Law Firms Seek Agilon Health Investors Ahead of March 2 Lead Plaintiff Deadline in Securities Case
The suit stems from agilon’s August 2025 guidance suspension that preceded a steep share-price decline.
Overview
- Notices from Rosen Law, Levi & Korsinsky, and Faruqi urge shareholders to seek lead status or join the case by March 2, 2026.
- Complaints allege the company issued unattainable 2025 guidance and overstated the immediate gains from risk-reduction “strategic actions.”
- The proposed class covers purchases between February 26, 2025 and August 4, 2025.
- Agilon disclosed the suspension of full-year 2025 guidance on August 4, 2025, and the stock fell about 51% the next day.
- No class has been certified, multiple firms are vying for lead roles, and Kuehn Law is probing potential fiduciary-duty breaches by officers and directors.